RITA Medical Systems Holds Annual Meeting of Stockholders
08 Junio 2006 - 6:30AM
PR Newswire (US)
FREMONT, Calif., June 8 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA) today announced that the Company held
its Annual Meeting of Stockholders on Wednesday, June 7, 2006, at
its corporate headquarters in Fremont, CA, as scheduled. A quorum
of stockholders was present in person or by proxy. All proposals
submitted to the Company's stockholders were approved, including
the reelection of two Class III directors to the Board of Directors
for three-year terms; the amendment to the Company's 2005 Stock and
Incentive Plan to increase the number of shares of common stock
issuable under the plan by an additional 500,000 shares; and the
ratification of the appointment of Stonefield Josephson, Inc. as
the Company's independent registered public accounting firm for the
current fiscal year. The directors reelected to serve until the
Company's 2009 Annual Meeting are Joseph DeVivo, President and
Chief Executive Officer of the Company; and Randy Lindholm, a
consultant to several life sciences companies. The names of the
Class I and Class II directors whose terms expire at the Company's
2007 and 2008 Annual Meetings, respectively, are Vincent Bucci,
President of Health Policy Associates, Inc.; Scott Halsted, General
Partner and Principal at Morgan Stanley, Dean Witter Venture
Partners; Steve LaPorte, Retired Medtronic, Inc. executive; James
E. Brands, Principal, Brands & Co.; Thomas J. Dugan, Senior
Vice President, Marketing & Business Development at SonoSite,
Inc.; and Wesley E. Johnson, Jr., General Manager of Abbott Spine,
S.A., a division of Abbott Laboratories. About RITA Medical
Systems, Inc. RITA Medical Systems develops, manufactures and
markets innovative products for cancer patients including
radiofrequency ablation (RFA) systems for treating cancerous tumors
as well as percutaneous vascular and spinal access systems. The
Company distributes the LC Bead(TM) (Biocompatibles, UK) product
which is used in arterial embolization of hypervascular tumors and
arteriovenous malformations and has U.S. Food and Drug
Administration (FDA) marketing clearance in the U.S. The Company's
oncology product lines include implantable ports, some of which
feature its proprietary Vortex(R) technology; tunneled central
venous catheters; and safety infusion sets and peripherally
inserted central catheters used primarily in cancer treatment
protocols. The radiofrequency product line also includes the HABIB
4X resection device which coagulates a surgical resection plane and
is designed to facilitate a fast dissection in order to minimize
blood loss and blood transfusion during surgery. The proprietary
RITA RFA system uses radiofrequency energy to heat tissue to a high
enough temperature to ablate it or cause cell death. In March 2000,
RITA became the first RFA Company to receive specific FDA clearance
for unresectable liver lesions in addition to its previous general
FDA clearance for the ablation of soft tissue. In October 2002,
RITA again became the first company to receive specific FDA
clearance, this time for the palliation of pain associated with
metastatic lesions involving bone. The RITA Medical Systems website
is at http://www.ritamedical.com/. The statements in this news
release are not intended to predict the Company's future and
financial operating performance. Information regarding risks and
uncertainties that could cause actual results to differ materially
from those in forward-looking statements is included in the
Company's filings with the Securities and Exchange Commission.
DATASOURCE: RITA Medical Systems, Inc. CONTACT: Joseph DeVivo,
President and CEO of RITA Medical Systems, Inc., +1-510-771-0400;
or investors, Doug Sherk, , or Jennifer Beugelmans, both at
+1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, or ,
all of EVC Group, for RITA Medical Systems, Inc. Web site:
http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024